Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities

[1]  Massimo Rizzi,et al.  Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy , 2019, Brain : a journal of neurology.

[2]  J. Szaflarski,et al.  The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy , 2017, Neurocase.

[3]  W. Catterall,et al.  Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome , 2017, Proceedings of the National Academy of Sciences.

[4]  A. Teixeira,et al.  Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels , 2017, Epilepsy & Behavior.

[5]  O. Devinsky,et al.  Cannabinoids as hippocampal network administrators , 2017, Neuropharmacology.

[6]  J. Szaflarski,et al.  Interactions between cannabidiol and commonly used antiepileptic drugs , 2017, Epilepsia.

[7]  P. Buckmaster,et al.  Seizure frequency correlates with loss of dentate gyrus GABAergic neurons in a mouse model of temporal lobe epilepsy , 2017, The Journal of comparative neurology.

[8]  D. Friedman,et al.  Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open‐label clinical study with cannabidiol , 2017, Epilepsia.

[9]  Charlotte E. Ridler.  Epilepsy: Cannabidiol reduces seizure frequency in Dravet syndrome , 2017, Nature Reviews Neurology.

[10]  A. Comi,et al.  Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome. , 2017, Pediatric neurology.

[11]  R. Pacifici,et al.  Neurological Disorders in Medical Use of Cannabis: An Update. , 2017, CNS & neurological disorders drug targets.

[12]  J. Kehne,et al.  Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP) , 2017, Neurochemical Research.

[13]  Orrin Devinsky,et al.  Cannabinoids in treatment-resistant epilepsy: A review , 2017, Epilepsy & Behavior.

[14]  Benjamin J. Whalley,et al.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection , 2017, Epilepsy & Behavior.

[15]  I. McGregor,et al.  An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use , 2017, Epilepsy & Behavior.

[16]  D. Prockop,et al.  Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus , 2017, Proceedings of the National Academy of Sciences.

[17]  J. Hallak,et al.  Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy , 2017, Front. Pharmacol..

[18]  C. Aguirre-Velázquez.  Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy , 2017, Neurology research international.

[19]  I. Galatzer-Levy,et al.  Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review , 2017, Depression and anxiety.

[20]  K. Nickels.  Cannabidiol in Patients with Intractable Epilepsy Due to TSC: A Possible Medication but Not a Miracle , 2017, Epilepsy currents.

[21]  C. Borlongan,et al.  Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms , 2017, Neuropsychiatric disease and treatment.

[22]  O. Devinsky,et al.  Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases , 2017, Journal of child neurology.

[23]  K. Knupp,et al.  Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients , 2017, Epilepsia.

[24]  Eugen Trinka,et al.  25 years of advances in the definition, classification and treatment of status epilepticus , 2017, Seizure.

[25]  M. Elsohly,et al.  Phytochemistry of Cannabis sativa L. , 2017, Progress in the chemistry of organic natural products.

[26]  Orrin Devinsky,et al.  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. , 2017, The New England journal of medicine.

[27]  W. Löscher.  The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach? , 2016, Neurochemical Research.

[28]  E. Thiele,et al.  Cannabidiol as a new treatment for drug‐resistant epilepsy in tuberous sclerosis complex , 2016, Epilepsia.

[29]  R. Martín-Santos,et al.  Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol , 2016, Front. Pharmacol..

[30]  R. Ransohoff.  How neuroinflammation contributes to neurodegeneration , 2016, Science.

[31]  T. Cummins,et al.  Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol. , 2016, Brain : a journal of neurology.

[32]  F. Rincon,et al.  Status Epilepticus: Epidemiology and Public Health Needs , 2016, Journal of clinical medicine.

[33]  U. Egert,et al.  Seizure-Induced Motility of Differentiated Dentate Granule Cells Is Prevented by the Central Reelin Fragment , 2016, Front. Cell. Neurosci..

[34]  F. Tang,et al.  Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis , 2016, Current neuropharmacology.

[35]  R. Koyama.  Dentate Circuitry as a Model to Study Epileptogenesis. , 2016, Biological & pharmaceutical bulletin.

[36]  S. Shorvon,et al.  Recent advances in status epilepticus. , 2016, Current opinion in neurology.

[37]  F. Piscitelli,et al.  Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome , 2016, Pharmacology research & perspectives.

[38]  Anup D. Patel,et al.  Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial , 2016, The Lancet Neurology.

[39]  O. B. Yosef,et al.  CBD-enriched medical cannabis for intractable pediatric epilepsy The current Israeli experience , 2016, Seizure.

[40]  I. Rosemergy,et al.  Cannabidiol oil in the treatment of super refractory status epilepticus. A case report , 2016, Seizure.

[41]  E. Aronica,et al.  Immunity and Inflammation in Epilepsy. , 2016, Cold Spring Harbor perspectives in medicine.

[42]  F. Khodagholi,et al.  Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure , 2016, Journal of Molecular Neuroscience.

[43]  A. Shetty,et al.  Resveratrol Treatment after Status Epilepticus Restrains Neurodegeneration and Abnormal Neurogenesis with Suppression of Oxidative Stress and Inflammation , 2015, Scientific Reports.

[44]  D. Araújo,et al.  Temporal lobe epilepsy patients with severe hippocampal neuron loss but normal hippocampal volume: Extracellular matrix molecules are important for the maintenance of hippocampal volume , 2015, Epilepsia.

[45]  J. Crippa,et al.  Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release. , 2015, Neurotoxicology.

[46]  N. Tajiri,et al.  Intravenous Bone Marrow Stem Cell Grafts Preferentially Migrate to Spleen and Abrogate Chronic Inflammation in Stroke , 2015, Stroke.

[47]  R. Tsien,et al.  Cannabinoids and Epilepsy , 2015, Neurotherapeutics.

[48]  E. Thiele,et al.  Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy , 2015, Epilepsia.

[49]  C. You,et al.  High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect. , 2015, International journal of clinical and experimental medicine.

[50]  J. E. Peixoto-Santos,et al.  Increased frequency of hippocampal sclerosis ILAE type 2 in patients with mesial temporal lobe epilepsy with normal episodic memory. , 2015, Brain : a journal of neurology.

[51]  Charuta N. Joshi,et al.  Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report. , 2015, Pediatric neurology.

[52]  B. A. David,et al.  Cannabidiol Rescues Acute Hepatic Toxicity and Seizure Induced by Cocaine , 2015, Mediators of inflammation.

[53]  K. Knupp,et al.  Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy , 2015, Epilepsy & Behavior.

[54]  D. Coulter,et al.  Role of astrocytes in epilepsy. , 2015, Cold Spring Harbor perspectives in medicine.

[55]  D. Deutsch,et al.  Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)* , 2015, The Journal of Biological Chemistry.

[56]  N. Tajiri,et al.  Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities , 2015, Neuropsychiatric disease and treatment.

[57]  G. Mathern,et al.  Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: Result of Epilepsia's survey , 2015, Epilepsia.

[58]  A. Shetty,et al.  Hippocampal injury-induced cognitive and mood dysfunction, altered neurogenesis, and epilepsy: Can early neural stem cell grafting intervention provide protection? , 2014, Epilepsy & Behavior.

[59]  A. Verrotti,et al.  Epilepsy and its main psychiatric comorbidities in adults and children , 2014, Journal of the Neurological Sciences.

[60]  K. Yamagata,et al.  Role of Inflammatory Mediators in the Pathogenesis of Epilepsy , 2014, Mediators of inflammation.

[61]  Benjamin J. Whalley,et al.  Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. , 2014, ACS chemical neuroscience.

[62]  Benjamin J. Whalley,et al.  Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders , 2014, Epilepsia.

[63]  Benjamin J. Whalley,et al.  Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se , 2014, Neuroscience Letters.

[64]  J. Engel,et al.  Past and Present Definitions of Epileptogenesis and Its Biomarkers , 2014, Neurotherapeutics.

[65]  H. Scharfman,et al.  Is plasticity of GABAergic mechanisms relevant to epileptogenesis? , 2014, Advances in experimental medicine and biology.

[66]  P. Buckmaster.  Does mossy fiber sprouting give rise to the epileptic state? , 2014, Advances in experimental medicine and biology.

[67]  B. Porter,et al.  Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy , 2013, Epilepsy & Behavior.

[68]  Benjamin J. Whalley,et al.  Cannabidivarin‐rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor‐independent mechanism , 2013, British journal of pharmacology.

[69]  C. Haas,et al.  Differential vulnerability of interneurons in the epileptic hippocampus , 2013, Front. Cell. Neurosci..

[70]  Manisha N. Patel,et al.  Mitochondrial involvement and oxidative stress in temporal lobe epilepsy. , 2013, Free radical biology & medicine.

[71]  S. Couillard-Després,et al.  Neurogenesis and neuronal regeneration in status epilepticus , 2013, Epilepsia.

[72]  Maria Thom,et al.  International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: A Task Force report from the ILAE Commission on Diagnostic Methods , 2013, Epilepsia.

[73]  N. Naderi,et al.  The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice , 2013, Epilepsy & Behavior.

[74]  R. Dingledine,et al.  The role of inflammation in epileptogenesis , 2013, Neuropharmacology.

[75]  D. Rusakov,et al.  Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses , 2013, Proceedings of the National Academy of Sciences.

[76]  P. Mareš,et al.  NMDA and AMPA receptors: development and status epilepticus. , 2013, Physiological research.

[77]  L. Mestre,et al.  Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress , 2012, Cell Death and Disease.

[78]  Benjamin J. Whalley,et al.  Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures , 2011, Seizure.

[79]  E. Florek,et al.  [Marihuana and cannobinoids as medicaments]. , 2012, Przeglad lekarski.

[80]  G. Booz.  Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. , 2011, Free radical biology & medicine.

[81]  A. Köfalvi,et al.  Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. , 2011, European journal of pharmacology.

[82]  A. Shetty,et al.  Acute Seizures in Old Age Leads to a Greater Loss of CA1 Pyramidal Neurons, an Increased Propensity for Developing Chronic TLE and a Severe Cognitive Dysfunction. , 2011, Aging and disease.

[83]  Tallie Z. Baram,et al.  The role of inflammation in epilepsy , 2011, Nature Reviews Neurology.

[84]  Benjamin J. Whalley,et al.  Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo , 2010, Journal of Pharmacology and Experimental Therapeutics.

[85]  A. Shetty,et al.  Decreased neuronal differentiation of newly generated cells underlies reduced hippocampal neurogenesis in chronic temporal lobe epilepsy , 2009, Hippocampus.

[86]  J. Stockman.  Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets , 2010 .

[87]  L. Petrocellis,et al.  Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels , 2010, Journal of Neuroimmune Pharmacology.

[88]  A. Shetty,et al.  Vulnerability of hippocampal GABA‐ergic interneurons to kainate‐induced excitotoxic injury during old age , 2009, Journal of cellular and molecular medicine.

[89]  B. Platt,et al.  Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+ Levels , 2009, The Journal of Neuroscience.

[90]  Y. Khalifa,et al.  Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. , 2008, Investigative ophthalmology & visual science.

[91]  A. Shetty,et al.  Status epilepticus during old age is not associated with enhanced hippocampal neurogenesis , 2008, Hippocampus.

[92]  István Katona,et al.  Endocannabinoid signaling as a synaptic circuit breaker in neurological disease , 2008, Nature Medicine.

[93]  H. Scharfman,et al.  Relevance of Seizure‐Induced Neurogenesis in Animal Models of Epilepsy to the Etiology of Temporal Lobe Epilepsy , 2007, Epilepsia.

[94]  K. Abe,et al.  Repeated treatment with cannabidiol but not Δ9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance , 2007, Neuropharmacology.

[95]  V. Cuomo,et al.  Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. , 2007, British journal of pharmacology.

[96]  C. Hillard,et al.  Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[97]  A. Shetty,et al.  Hippocampal neurodegeneration, spontaneous seizures, and mossy fiber sprouting in the F344 rat model of temporal lobe epilepsy , 2006, Journal of neuroscience research.

[98]  Masahiko Watanabe,et al.  The CB1 Cannabinoid Receptor Is the Major Cannabinoid Receptor at Excitatory Presynaptic Sites in the Hippocampus and Cerebellum , 2006, The Journal of Neuroscience.

[99]  G. Marsicano,et al.  Neuromodulatory functions of the endocannabinoid system. , 2006, Journal of endocrinological investigation.

[100]  M. Elsohly,et al.  Chemical constituents of marijuana: the complex mixture of natural cannabinoids. , 2005, Life sciences.

[101]  A. Shetty,et al.  Repair of the Injured Adult Hippocampus through Graft-Mediated Modulation of the Plasticity of the Dentate Gyrus in a Rat Model of Temporal Lobe Epilepsy , 2005, The Journal of Neuroscience.

[102]  A. Shetty,et al.  Chronic temporal lobe epilepsy is associated with severely declined dentate neurogenesis in the adult hippocampus , 2004, Neurobiology of Disease.

[103]  M. Pistis,et al.  Endocannabinoids Mediate Presynaptic Inhibition of Glutamatergic Transmission in Rat Ventral Tegmental Area Dopamine Neurons through Activation of CB1 Receptors , 2004, The Journal of Neuroscience.

[104]  I. Izquierdo,et al.  Effect of cannabidiol and of other Cannabis sativa compounds on hippocampal seizure discharges , 2004, Psychopharmacologia.

[105]  D. Turner,et al.  Fetal Hippocampal Grafts Containing CA3 Cells Restore Host Hippocampal Glutamate Decarboxylase-Positive Interneuron Numbers in a Rat Model of Temporal Lobe Epilepsy , 2000, The Journal of Neuroscience.

[106]  N. Fountain.  Status Epilepticus: Risk Factors and Complications , 2000, Epilepsia.

[107]  D. Turner,et al.  Aging impairs axonal sprouting response of dentate granule cells following target loss and partial deafferentation , 1999, The Journal of comparative neurology.

[108]  Ken Mackie,et al.  Presynaptically Located CB1 Cannabinoid Receptors Regulate GABA Release from Axon Terminals of Specific Hippocampal Interneurons , 1999, The Journal of Neuroscience.

[109]  B. Thomas,et al.  Comparative receptor binding analyses of cannabinoid agonists and antagonists. , 1998, The Journal of pharmacology and experimental therapeutics.

[110]  W. Hauser,et al.  Incidence of status epilepticus in Rochester, Minnesota, 1965-1984 , 1998, Neurology.

[111]  D. Geschwind,et al.  Dentate Granule Cell Neurogenesis Is Increased by Seizures and Contributes to Aberrant Network Reorganization in the Adult Rat Hippocampus , 1997, The Journal of Neuroscience.

[112]  D. Turner,et al.  Fetal Hippocampal Cells Grafted to Kainate-Lesioned CA3 Region of Adult Hippocampus Suppress Aberrant Supragranular Sprouting of Host Mossy Fibers , 1997, Experimental Neurology.

[113]  M. C. McBride,et al.  Status epilepticus. , 2016, Pediatrics in review.

[114]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[115]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[116]  B. Alger,et al.  Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[117]  A. Konnerth,et al.  Synaptic‐ and agonist‐induced excitatory currents of Purkinje cells in rat cerebellar slices. , 1991, The Journal of physiology.

[118]  M. Brodie.  Status epilepticus in adults , 1990, The Lancet.

[119]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[120]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[121]  R. Mechoulam,et al.  Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. , 1982, European journal of pharmacology.

[122]  H. Brill.  Marihuana: The First Twelve Thousand Years. , 1981, Journal of psychoactive drugs.

[123]  D. Jackson,et al.  Interaction of Δ9‐tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions , 1975, The Journal of pharmacy and pharmacology.